MEDEXUS PHARMA

Company Overview

Medexus Pharmaceuticals, Inc. is a leading innovative specialty pharmaceutical company with a strong North American commercial platform. Our product portfolio features leading products that address a variety of diseases, including allergy, dermatology, hematology, oncology and rheumatology.

The leading prescription products are Rasuvo and Metoject, unique formulations of methotrexate (auto-injector and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, an innovative allergy medication with a unique mode of action; IXINITY, for control & prevention of bleeding episodes & for perioperative management of patients with Hemophilia B; Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery; and Trecondyv, indicated in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (alloHSCT).

Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

Apr 2 2024, 7:30 AM EDT

FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients

Mar 26 2024, 7:53 AM EDT

Medexus Announces Fiscal Q3 2024 Results

Feb 7 2024, 5:58 PM EST

Management Team

Ken d'Entremont
Chief Executive Officer and Director

Marcel Konrad
Chief Financial Officer

Ian C Wildgoose Brown
General Counsel

Michael Adelman
General Manager, U.S. Operations

Richard Labelle
General Manager, Canadian Operations

Medexus Pharmaceuticals, Inc.

10 King Street East, Suite 600
Toronto, ON M5C 1C3
Canada

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.